When was Lumos Pharma founded?

Lumos Pharma was founded in 1999 and raised its 1st funding round 9 years after it was founded.

Where is Lumos Pharma located?

Lumos Pharma is headquartered in Austin, United States. It is registered at 2503 S LOOP DR STE 5100,AMES,IA,50010,0.

How many employees does Lumos Pharma have?

As of May 31, 2026, the latest employee count at Lumos Pharma is 49.

Is Lumos Pharma a funded company?

Lumos Pharma is a funded company, having raised a total of $48M across 9 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 17, 2008.

When was the latest funding round of Lumos Pharma?

Lumos Pharma's latest funding was a $***** Series B round on Sep 08, 2016, with participation from 1 investor. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $711M in funding in 2026 to date.

What is the annual revenue of Lumos Pharma?

Annual revenue of Lumos Pharma is between $1M and $10M as on Dec 31, 2023

Where does Lumos Pharma rank among its competitors?

Lumos Pharma ranks 71st amongst 277 active competitors, of which 78 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Lumos Pharma?

Lumos Pharma's top competitors include BridgeBio, Alnylam and Alexion. Among them, BridgeBio secured the most recent funding round in April, 2024.

Lumos Pharma - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Biopharmaceutical company transforming lives through therapeutics for rare diseases. Focused on developing innovative therapies for unmet medical needs, particularly in pediatric growth hormone deficiency (PGHD). The company is dedicated to helping patients and families through advocacy and compassionate use programs. They are committed to advancing clinical research and fostering partnerships to bring novel treatments to market. The company's pipeline includes LUM-201, an oral therapeutic candidate for PGHD. They are involved in clinical trials and presentations to share their research findings. The company emphasizes a culture of collaboration and innovation, seeking to make a significant impact on the lives of individuals affected by rare conditions.

Website: lumos-pharma.com
Social
Registered Address: 2503 S LOOP DR STE 5100,AMES,IA,50010,0

Key Metrics

Founded Year

1999

Location

Austin, United States

Stage

Series B

Total Funding

$48M in 9 rounds

Latest Funding Round

Series B, Sep 08, 2016, $*****

Investors

New Enterprise Associates & 9 more

Ranked

71^st among 277 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2023

Employee Count

49 as on May 31, 2026

Similar Companies

BridgeBio & 311 more

View Lumos Pharma's full profile

Lumos Pharma is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
LUMOS PHARMA, INC. CIN: 42-1491350 , United States, Active		$1M - $10M (As on Dec 31, 2023)	28 (As on Dec 31, 2020)	-
Lumos Pharma, Inc. CIN: 32053894724 , United States, Active	May 09, 2014	-	-	-

Lumos Pharma has raised a total funding of $48M over 9 rounds. Its first funding round was on Sep 17, 2008. Its latest funding round was a Series B round on Sep 08, 2016 for $*****. 1 investor participated in its latest round. Lumos Pharma has 10 institutional investors.

Here is the list of recent funding rounds of Lumos Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 08, 2016	1210699	Series B	6353032	4511326	5088165	9588060
Apr 18, 2016	5708098	Series B	8012295	4357926	3358910	New Enterprise Associates & 4 more
May 04, 2015	4248251	Grant (prize money)	6120692	8323710	7397505	Wellcome Trust

Access funding benchmarks and valuations. Sign up today!

View details of Lumos Pharma's funding rounds and investors

Lumos Pharma's employee count trend

Lumos Pharma has 49 employees as of May 26. Here is Lumos Pharma's employee count trend over the years:

Uncover Lumos Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lumos Pharma include BridgeBio, Alnylam and Alexion. Here is the list of Top 10 competitors of Lumos Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Flagship Pioneering, Arch Venture Partners ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
10th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	70/100
71st	Lumos Pharma 1999, Austin (United States), Series B	Biopharmaceutical company transforming lives through therapeutics for rare diseases	$48M	Deerfield, New Enterprise Associates & 8 others	52/100